Foghorn Therapeutics (FHTX) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 26.1% versus a loss of 55.8%. Over five years, FHTX leads with a -83.9% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $118.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | HURA |
|---|---|---|
| Share price | $2.00 | $1.96 |
| Market cap | $118.77M | $124.90M |
| 1-day change | +0.50% | +1.55% |
| YTD return | -63.15% | +154.95% |
| 1-year return | -55.78% | -26.05% |
| 5-year return | -83.93% | -99.87% |
| EPS (TTM) | $-0.98 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $3.43 |
| 52-week low | $1.79 | $0.41 |
| Distance from 52-week high | -73.72% | -42.86% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +200.00% | +310.20% |
| Average volume | 629.61K | 250.11K |
| Shares outstanding | 59.39M | 63.73M |
| Employees | 106 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed FHTX by 29.7 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
FHTX vs HURA FAQ
Which is bigger, Foghorn Therapeutics or TuHURA Biosciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $118.77M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or HURA?
HURA returned -26.05% over the past 12 months, compared with -55.78% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.